CELSET launches SOLTOX botulinum toxin for international markets
South Korean biotechnology firm CELSET has introduced SOLTOX, a botulinum toxin type A product, as it expands its presence in the global medical aesthetics sector.
Seoul-based biotech company CELSET has officially launched SOLTOX, a botulinum toxin type A product designed for the medical aesthetics market. The move signals the company's intent to compete in a global sector that has seen significant growth in recent years, particularly driven by the increased accessibility of non-surgical cosmetic treatments.
South Korean manufacturers have become prominent players in the toxin market, often challenging established incumbents through pricing and production scalability. CELSET’s entry into the international market follows this trend, leveraging local manufacturing capabilities to target regions where aesthetic procedures are becoming more mainstream.
Success for the new brand will depend on securing regulatory approvals in key international jurisdictions. CELSET’s entry highlights the continued transformation of the South Korean biopharmaceutical sector into a major exporter of specialized medical products.